Investor Presentaiton

ORION Orion's key clinical trials with darolutamide Clinical trial and treatment Indication Primary endpoint and results ARAMIS darolutamide + ADT nmCRPC Key secondary endpoints Status Metastasis free survival prolongation by 22.0 months, 59% risk reduction (HR=0.41, p<0.001) Overall survival Overall survival 31% risk reduction (HR=0.69, p=0.003) Approved 11 ARASENS darolutamide + ADT MHSPC + docetaxel 32.5% risk reduction (HR 0.675, p<0.001) ARANOTE MHSPC darolutamide + ADT ARASTEP BCR darolutamide + ADT Radiological progression-free survival (study ongoing) Radiological progression-free survival (study ongoing) Time to castration resistant PC 64% risk reduction (HR=0.36, p<0,001) Approved Overall survival (study ongoing) Metastasis free survival Time to castration resistant PC Overall survival Overall incidence of treatment-emergent adverse events was similar between treatment arms (darolutamide group vs. placebo group) both in ARAMIS and ARASENS trials = ADT androgen deprivation therapy nmCRPC = non-metastatic castration-resistant prostate cancer mHSPC metastatic hormone-sensitive prostate cancer BCR biochemical relapse Orion develops darolutamide in collaboration with Bayer. Phase III ongoing Phase III ongoing Investor Presentation Orion Corporation

View entire presentation